Klein Lawrence Otto
SEC-identified person · CIK 1762583 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Oruka Therapeutics, Inc. ORKA | Director · President and CEO | filed 2024–2026 |
| Jade Biosciences, Inc. JBIO | Director | filed 2025–2026 |
| Jasper Therapeutics, Inc. JSPR | Director | filed 2021–2023 |
| Crispr Therapeutics AG CRSP | Chief Business Officer | filed 2019–2022 |
| Dyne Therapeutics, Inc. DYN | Director | filed 2020–2022 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.